Two Los Angeles Child Welfare Agencies Announce Intent to Merge

first_img More Cool Stuff Subscribe Left to right: Ritchie L. Geisel, Bienvenidos president and CEO, and Joseph M. Costa, Hillsides CEO.On April 14, the boards of directors of Hillsides and Bienvenidos signed a Memorandum of Understanding and Term Sheet stating their intent to merge. Several developments over the past four years have prompted these two leading child welfare agencies in Southern California to explore an affiliation with one another, consolidate missions to leverage their success, and increase their collective impact.Hillsides provides high quality care, advocacy, and innovative services that promote safe, permanent environments where children and youth can thrive. Headquartered in Pasadena, the agency serves more than 6,240 children and families in Los Angeles County throughout its 26 sites, including school-based mental health offices in Los Angeles, Pasadena, and Baldwin Park Unified School Districts.Bienvenidos is a compassionate community of care dedicated to healing children, strengthening families, and transforming communities. Serving 7,000 children and families annually, the agency operates its programs out of nine locations in East Los Angeles and San Gabriel Valley. This includes licensed foster homes that serve Los Angeles, Orange, San Bernardino and Riverside Counties.The developments driving this merger are the Continuum of Care Reform legislation (AB 403), the Affordable Care Act, the integration of Los Angeles County’s health and behavioral health services, and the creation of the Nonprofit Sustainability Initiative by Los Angeles area foundations to encourage increased collaboration.In particular, AB 403, which took effect in January, 2016 calls for a spectrum of services to accelerate the path to permanency for children in foster care, whether through successful reunification or, when appropriate, adoption.“Access to a comprehensive array of services requires greater levels of collaboration among children’s service providers,” says Joseph M. Costa, Hillsides CEO. “To enhance our service delivery system and respond to these external factors, the leadership of Hillsides and Bienvenidos began discussions last fall to look for ways to achieve cost-effective synergy, and this led to the intent to merge.”Both Hillsides and Bienvenidos will retain their individual names with Bienvenidos becoming an affiliate of Hillsides.According to Bienvenidos President and CEO Ritchie L. Geisel, the agencies’ combined resources and workforce of 600 will increase their impact in Los Angeles and surrounding counties. Together, the enhanced services will empower children, youth, and families who have experienced trauma to create lasting changes in their lives. “Our clients’ resilience and resolve to improve their lives inspire us every day to further our collective mission,” Geisel says.The leadership of both agencies recognizes their similar missions and complementary programs are well suited for a merger. Combined with the additional programs each brings to the table, this merger helps them align with current legislation, public policy, and best practice models.“Together we will be able to fulfill our shared vision and provide leadership during this paradigm shift in child welfare,” said Costa, adding that their common set of values will enable them to continue serving the needs of more than 13,000 children, youth, and families, collectively. Make a comment 0 commentsShareShareTweetSharePin it Community News Pasadena Will Allow Vaccinated People to Go Without Masks in Most Settings Starting on Tuesday First Heatwave Expected Next Week Home of the Week: Unique Pasadena Home Located on Madeline Drive, Pasadena HerbeautyFinding The Right Type Of Workout For You According AstrologyHerbeautyHerbeautyHerbeautyA Woman Being Deceptive About Her Age Is Nothing New!HerbeautyHerbeautyHerbeauty8 Easy Exotic Meals Anyone Can MakeHerbeautyHerbeautyHerbeautyIs It Bad To Give Your Boyfriend An Ultimatum?HerbeautyHerbeautyHerbeautyRemove Belly Fat Without Going Under The KnifeHerbeautyHerbeautyHerbeauty11 Signs Your Perfectionism Has Gotten Out Of ControlHerbeautyHerbeauty EVENTS & ENTERTAINMENT | FOOD & DRINK | THE ARTS | REAL ESTATE | HOME & GARDEN | WELLNESS | SOCIAL SCENE | GETAWAYS | PARENTS & KIDScenter_img Name (required)  Mail (required) (not be published)  Website  faithfernandez More » ShareTweetShare on Google+Pin on PinterestSend with WhatsApp,Donald CommunityPCC- COMMUNITYVirtual Schools PasadenaHomes Solve Community/Gov/Pub SafetyPasadena Public WorksPASADENA EVENTS & ACTIVITIES CALENDARClick here for Movie Showtimes Community News Two Los Angeles Child Welfare Agencies Announce Intent to Merge From STAFF REPORTS Published on Friday, April 15, 2016 | 2:43 pm Community News Get our daily Pasadena newspaper in your email box. Free.Get all the latest Pasadena news, more than 10 fresh stories daily, 7 days a week at 7 a.m. Top of the News Business News Pasadena’s ‘626 Day’ Aims to Celebrate City, Boost Local Economy Your email address will not be published. Required fields are marked *last_img read more

Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference

first_img Twitter TAGS  WhatsApp Facebook Pinterest Facebook WhatsApp Twittercenter_img Inhibikase Therapeutics to Present at the American Society of Experimental Neurotherapeutics (ASENT) Conference Local NewsBusiness By Digital AIM Web Support – February 22, 2021 Pinterest ATLANTA, Feb. 22, 2021 /PRNewswire/ — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease and related disorders, today announced that it will present findings from its oral therapy studies for its lead agent IkT-148009 in progressive disease models of Parkinson’s at the American Society of Experimental Neurotherapeutics (ASENT) 2021 Annual Meeting, being held virtually from February 22 – 25, 2021. Inhibikase’s President and Chief Executive Officer, Milton Werner, Ph.D. will describe the benefits observed following therapeutic, oral, daily administration of IkT-148009 in humanized mouse models of slowly progressive Parkinson’s disease (PD). These outcomes suggest a mechanistic understanding of the role of alpha-synuclein plaques in the onset of disease. Details for the presentation are below: Event: American Society of Experimental Neurotherapeutics Conference Session: Symposium on Parkinson’s Disease: New Approaches Presentation Title: Disease modification of Parkinson’s Disease through oral kinase inhibitor therapy Presentation Date: Thursday, February 25, 2021 Time: 10:20-10:40am ET Following the presentation, there will be a live panel discussion and Q&A session from 11:00-11:15am ET. “We are excited to share some of the preclinical results of our IkT-148009 program at the ASENT 2021 conference. C-Abl is believed to be activated by the presence of alpha-synuclein plaque within affected neurons and subsequently, chemically modifies them, which we believe is a key event initiating the disease process in PD,” stated Dr. Werner. “We believe that IkT-148009, may have the potential to alter the course of PD and transform the lives of millions of patients worldwide.” IkT-148009 is intended to be a once daily oral therapy to modify the progression of PD and has demonstrated functional recovery in animal models of Parkinson’s disease in the brain and gastrointestinal, or GI, tract, two major organs affected by PD in humans. IkT-148009 is currently in Phase 1 clinical trials for the treatment of PD. About Inhibikase ( www.inhibikase.com ) Inhibikase (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease and related disorders. Inhibikase’s multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain. Inhibikase is currently dosing patients in its Phase I, randomized single ascending dose and multiple ascending dose in study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts. Forward-Looking Statements This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,” “will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements, including statements regarding the closing of the initial public offering and the proceeds of the initial public offering, are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Inhibikase’s filings with the SEC, including its registration statement on Form S-1, as amended (File No. 333-240036), including under the caption “Risk Factors.” Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Contacts: Company Contact: Milton H. Werner, PhD President & CEO 678-392-3419 [email protected] Investor Relations: Alex Lobo SternIR, Inc. [email protected] View original content to download multimedia: http://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-present-at-the-american-society-of-experimental-neurotherapeutics-asent-conference-301232095.html SOURCE Inhibikase Therapeutics, Inc.Copyright © 2021 PR Newswire Association LLC. All Rights Reserved. Previous articleIn Israel and beyond, virus vaccines bring political powerNext articleJuniper Research: Smart Traffic Management to Significantly Reduce Congestion and Emissions; Saving Cities $277 Billion by 2025 Digital AIM Web Supportlast_img read more